European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

On 18 September 2017, a marketing authorisation valid through the European Union (EU) was issued for midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy and for patients in complete response followed by midostaurin single...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESMO Open
Autors principals: Tzogani, Kyriaki, Yu, Yang, Meulendijks, Didier, Herberts, Carla, Hennik, Paula, Verheijen, Remy, Wangen, Torunn, Dahlseng Håkonsen, Gro, Kaasboll, Torny, Dalhus, Marianne, Bolstad, Bjorg, Salmonson, Tomas, Gisselbrecht, Christian, Pignatti, Francesco
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001097/
https://ncbi.nlm.nih.gov/pubmed/32392175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000606
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars